Zhongzhi Pharmaceutical Holdings Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Zhongzhi Pharmaceutical Holdings.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 11.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Little Excitement Around Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Earnings As Shares Take 26% Pounding
Aug 22
Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)
Jun 19Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation
May 10Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03
May 05Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03
Apr 21Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares
Feb 01These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well
May 24Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?
Aug 26Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet
Apr 28These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well
Jun 11Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)
May 06Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues
Apr 21Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?
Mar 29The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More
Mar 05Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?
Feb 15
What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?
Jan 14Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?
Dec 27If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late
Dec 14Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?
Nov 30Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 17In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zhongzhi Pharmaceutical Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 2,044 | 111 | -22 | 169 | N/A |
| 3/31/2024 | 2,047 | 137 | -46 | 135 | N/A |
| 12/31/2023 | 2,050 | 163 | -70 | 102 | N/A |
| 9/30/2023 | 2,062 | 164 | 18 | 168 | N/A |
| 6/30/2023 | 2,074 | 164 | 106 | 234 | N/A |
| 3/31/2023 | 1,950 | 135 | 151 | 259 | N/A |
| 12/31/2022 | 1,826 | 106 | 195 | 285 | N/A |
| 9/30/2022 | 1,766 | 84 | 147 | 263 | N/A |
| 6/30/2022 | 1,706 | 63 | 98 | 242 | N/A |
| 3/31/2022 | 1,726 | 57 | 44 | 210 | N/A |
| 12/31/2021 | 1,747 | 52 | -9 | 178 | N/A |
| 9/30/2021 | 1,750 | 93 | -46 | 132 | N/A |
| 6/30/2021 | 1,753 | 133 | -83 | 86 | N/A |
| 3/31/2021 | 1,678 | 136 | -54 | 90 | N/A |
| 12/31/2020 | 1,604 | 139 | -25 | 93 | N/A |
| 9/30/2020 | 1,524 | 133 | 29 | 120 | N/A |
| 6/30/2020 | 1,444 | 128 | 82 | 147 | N/A |
| 3/31/2020 | 1,393 | 121 | 92 | 157 | N/A |
| 12/31/2019 | 1,342 | 115 | 102 | 168 | N/A |
| 9/30/2019 | 1,282 | 106 | 88 | 160 | N/A |
| 6/30/2019 | 1,221 | 97 | 75 | 152 | N/A |
| 3/31/2019 | 1,182 | 91 | 39 | 116 | N/A |
| 12/31/2018 | 1,142 | 85 | 4 | 80 | N/A |
| 9/30/2018 | 1,106 | 82 | -15 | 55 | N/A |
| 6/30/2018 | 1,070 | 79 | -35 | 29 | N/A |
| 3/31/2018 | 1,007 | 74 | N/A | 40 | N/A |
| 12/31/2017 | 945 | 70 | N/A | 51 | N/A |
| 9/30/2017 | 874 | 65 | N/A | 52 | N/A |
| 6/30/2017 | 803 | 60 | N/A | 53 | N/A |
| 3/31/2017 | 767 | 57 | N/A | 51 | N/A |
| 12/31/2016 | 730 | 54 | N/A | 49 | N/A |
| 9/30/2016 | 715 | 52 | N/A | 41 | N/A |
| 6/30/2016 | 700 | 50 | N/A | 34 | N/A |
| 3/31/2016 | 694 | 65 | N/A | 45 | N/A |
| 12/31/2015 | 688 | 81 | N/A | 56 | N/A |
| 9/30/2015 | 671 | 91 | N/A | 80 | N/A |
| 6/30/2015 | 655 | 101 | N/A | 104 | N/A |
| 3/31/2015 | 625 | 94 | N/A | 113 | N/A |
| 12/31/2014 | 596 | 87 | N/A | 122 | N/A |
| 12/31/2013 | 483 | 38 | N/A | 45 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 3737's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 3737's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 3737's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 3737's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 3737's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 3737's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 12:27 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhongzhi Pharmaceutical Holdings Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung-yan Chan | ABCI Securities Company Limited |